secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001232524-23-000051
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharmaceuticals Reports Q3 2023 Revenue of $972M, Raises Full-Year Guidance
--------------------------------------------------------------------------------

- Xywav net product sales grew 30% year-over-year to $331.6M; total oxybate revenue annualizing at $1.9B
- Epidiolex net product sales up 9% to $213.7M; Rylaze up 43% to $104.9M
- Company raises 2023 total revenue guidance to $3.75-$3.875B and oncology guidance to $975M-$1.05B
- Plan to initiate zanidatamab rolling BLA submission this year for accelerated approval in 2L biliary tract cancers
- GAAP net income of $146.8M vs. loss of $19.6M in Q3 2022; non-GAAP adjusted net income $340.1M

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000123252423000051/0001232524-23-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000123252423000051/jazz-20231108.htm
  HTML page:      https://secwatch.observer/filing/0001232524-23-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer